Purdue will pay out millions in bonuses in bankruptcy case

Amy Baxter | | Health Exec | Policy & Regulations
Researchers found millions of heart failure patients who qualify for standard, guideline directed medical therapies, but did not receive it due to poor health literacy, limited access to care and medication costs.

Purdue Pharma, maker of the popular opioid OxyContin, will be allowed to dole out millions of dollars in bonuses to executives as the company declares bankruptcy as part of a $10 billion settlement to resolve thousands of lawsuits against the company for its role in the national opioid abuse and overdose epidemic.

Specifically, the company will pay about $26 million in wages, benefits and bonuses, according to CNN.

Bankruptcy proceedings for Purdue began on Tuesday, Sept. 17, with a final hearing held on Oct. 10. Once the filings are complete, Purdue will provide more than $10 billion in funding to address the opioid crisis and the Sackler family, which owns the company, will cough up about $3 billion of their own fortune, CNN reported.

See the full story below:

Opioid-maker Purdue Pharma is allowed bonus payout in bankruptcy case

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Trump administration halts public communications from health agencies
Trump signs executive order to withdraw U.S. from the World Health Organization
DOJ sues Walgreens for allegedly filling ‘millions’ of illegal prescriptions
Another insurer sues CMS over star ratings, citing contractor error
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say
DEA wants to permanently anchor some COVID-era prescription regulations

Around the web

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Cardiovascular Business
FDA announces recall after Philips heart monitor software failed to send alerts—multiple deaths reported

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.